Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJWRQP)

Drug Name

Zanubrutinib Drug Info

Synonyms

RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27

Indication

Disease Entry	ICD 11	Status	REF
Mantle cell lymphoma	2A85.5	Approved	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]
Small lymphocytic lymphoma	2A82.0	Phase 3	[2]
Waldenstrom macroglobulinemia	2A85.4	Phase 3	[2]
B-cell lymphoma	2A86	Phase 1	[2]

Cross-matching ID

PubChem CID: 135905454
TTD Drug ID: DMJWRQP

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.838	3.897	5.053	5.897

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Mantle cell lymphoma

ICD Disease Classification

2A85.5

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.54E-01	0.24	0.56

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)